Regeneron Pharmaceuticals Inc

REGN XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

63B

Short interest (May 15)

2.7%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.25%

↓ 7.1%

Available Shares

↓ 11.4%

Price Chart

Company Overview

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0000872589

Asset Type: CS

Market Data

Market Cap: $63,209,549,173

Employees: 15,410

Status: Active

Short Interest

Current Borrow Fee 0.25%

Range: 0.25% - 0.40%

Available Shares 2M

Range: 1.4M - 1.7M

Recent Changes

Fee Change: ↑ 30.1%

Available Change: ↓ 8.6%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime